Members of the health plan will have access to Biocept's growing menu of circulating tumor cell and circulating tumor DNA tests.
Investigators will compare results using Biocept's platform in cerebrospinal fluid to current standard methods for diagnosing leptomeningeal metastases.
The company said in a filing with the US Securities and Exchange Commission that it failed to maintain compliance with the Nasdaq's minimum closing bid price requirement.
The maker of cancer biomarker assays reported record revenues of more than $1 million in the quarter compared to $164,858 in the prior-year period.
The company sold 9.1 million shares of its common stock and warrants to purchase up to 9.1 million more shares at a combined offering price of $1.10 per share.
The company is offering 9.1 million shares of its common stock, as well as warrants to purchase up to 9.1 million additional shares.
The University of Minnesota's Shilpa Gupta will work with Biocept on a study aimed at providing clinical support for the use of the firm's PD-L1 and AR tests.
Teneovita will distribute Biocept's test services to hospitals, oncology centers, and individual medical practices throughout the country.
Testing will be performed by Biocept in the US, and HarlePhil Ventures will sell, market, distribute, and collect reimbursements in the Philippines.
The firm's second quarter revenues grew more than seven times year over year based on a large increase in billable samples.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.